MX2024005431A - Degradadores bifuncionales de la cinasa progenitora hematopoyética y sus usos terapéuticos. - Google Patents

Degradadores bifuncionales de la cinasa progenitora hematopoyética y sus usos terapéuticos.

Info

Publication number
MX2024005431A
MX2024005431A MX2024005431A MX2024005431A MX2024005431A MX 2024005431 A MX2024005431 A MX 2024005431A MX 2024005431 A MX2024005431 A MX 2024005431A MX 2024005431 A MX2024005431 A MX 2024005431A MX 2024005431 A MX2024005431 A MX 2024005431A
Authority
MX
Mexico
Prior art keywords
therapeutic uses
hematopoietic progenitor
degraders
progenitor kinase
bifunctional
Prior art date
Application number
MX2024005431A
Other languages
English (en)
Spanish (es)
Inventor
Frederick Cohen
John Buell
Lan Wang
Mark Edward Zak
Ryan Pemberton
Hunter P Shunatona
Original Assignee
Nurix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nurix Therapeutics Inc filed Critical Nurix Therapeutics Inc
Publication of MX2024005431A publication Critical patent/MX2024005431A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2024005431A 2021-11-10 2022-11-09 Degradadores bifuncionales de la cinasa progenitora hematopoyética y sus usos terapéuticos. MX2024005431A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163263875P 2021-11-10 2021-11-10
PCT/US2022/049426 WO2023086399A1 (en) 2021-11-10 2022-11-09 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2024005431A true MX2024005431A (es) 2024-07-19

Family

ID=85132852

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005431A MX2024005431A (es) 2021-11-10 2022-11-09 Degradadores bifuncionales de la cinasa progenitora hematopoyética y sus usos terapéuticos.

Country Status (12)

Country Link
US (2) US12091426B2 (https=)
EP (1) EP4430052A1 (https=)
JP (1) JP2024543377A (https=)
KR (1) KR20240101654A (https=)
CN (1) CN118510786A (https=)
AR (1) AR127625A1 (https=)
AU (1) AU2022388571A1 (https=)
CA (1) CA3235913A1 (https=)
IL (1) IL312361A (https=)
MX (1) MX2024005431A (https=)
TW (1) TW202334170A (https=)
WO (1) WO2023086399A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN117126133A (zh) * 2023-08-14 2023-11-28 中国海洋大学 一种化合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600373YA (en) 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP7472103B2 (ja) 2018-08-22 2024-04-22 クルゲン(シャンハイ),インク. トロポミオシン受容体キナーゼ(trk)分解化合物とその使用方法
WO2020092528A1 (en) * 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
JP7503851B2 (ja) 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Hpk1の分解剤としてのヘテロ二官能性化合物
WO2021168197A1 (en) 2020-02-19 2021-08-26 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
US11739101B2 (en) * 2020-05-06 2023-08-29 Nurix Therapeutics, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Also Published As

Publication number Publication date
JP2024543377A (ja) 2024-11-21
KR20240101654A (ko) 2024-07-02
CN118510786A (zh) 2024-08-16
WO2023086399A1 (en) 2023-05-19
IL312361A (en) 2024-06-01
US20240018162A1 (en) 2024-01-18
AU2022388571A1 (en) 2024-05-09
CA3235913A1 (en) 2023-05-19
US12091426B2 (en) 2024-09-17
TW202334170A (zh) 2023-09-01
US20240400587A1 (en) 2024-12-05
AR127625A1 (es) 2024-02-14
EP4430052A1 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
MX2024002153A (es) Degradadores bifuncionales de las quinasas asociadas al receptor de interleucina-1 y uso terapeutico de estos.
MX2024005431A (es) Degradadores bifuncionales de la cinasa progenitora hematopoyética y sus usos terapéuticos.
MX2024006824A (es) Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos.
WO2020106642A8 (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
CR20230057A (es) Compuestos tríciclicos de urea como inhibidores de jak2 v617f
ZA202004100B (en) Diaryl macrocycles as modulators of protein kinases
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MY168762A (en) Certain chemical entities, compositions and methods
WO2018154380A8 (en) Compositions and methods for treatment of proprotein convertase subtilisin/kexin type 9 (pcsk9)-related disorders
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
MY159955A (en) Certain chemical entities, compositions and methods
MY200941A (en) (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n-bis(ethylene)phosphoramidate, compositions and methods for their use and preparation
EP4335517A3 (en) Administration and dosage of diaminophenothiazines
MX2009010984A (es) Moduladores de heterociclo cinasa de anillo fusionado.
PH12022551105A1 (en) Tyk2 pseudokinase ligands
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
JOP20200023A1 (ar) مركبات حلقية لولبية وطرق تصنيعها واستخدامها
PH12021553132A1 (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
MY200738A (en) Pyrazole magl inhibitors
AU2012240222A8 (en) Methods of treating central nervous system tumors
MX2024015127A (es) Compuestos triciclicos de triazolo como inhibidores de la diacilglicerol cinasa (dgk)
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
CR20240447A (es) Compuestos de urea tricíclica como inhibidores de v617f de jak2.
WO2017098051A3 (en) Combined preparations of pkm2 modulators and hmgb1